View stunning SlideShares in full-screen with the new iOS app!Introducing SlideShare for AndroidExplore all your favorite topics in the SlideShare appGet the SlideShare app to Save for Later — even offline
View stunning SlideShares in full-screen with the new Android app!View stunning SlideShares in full-screen with the new iOS app!
You can also request for sample page of abovemention reports on email@example.com
Pages : 104PDF - $ 2000 | Site Licence - $ 4000 $ | Enterprise License - $6000 |20% Off on above 1000$ Reports25% off on purchase of 2 reports and 30% on purchase of3 or more reports.Discount till 31st Dec. 2012.
Summary Global Markets Direct’s, Metastatic Hormone Refractory Prostate Cancer -Pipeline Review, H2 2012, provides an overview of the indication’stherapeutic pipeline. This report provides information on the therapeuticdevelopment for Metastatic Hormone Refractory Prostate Cancer, completewith latest updates, and special features on late-stage and discontinuedprojects. It also reviews key players involved in the therapeuticdevelopment for Metastatic Hormone Refractory Prostate Cancer. MetastaticHormone Refractory Prostate Cancer - Pipeline Review, Half Year is builtusing data and information sourced from Global Markets Direct’sproprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sitesand industry-specific third party sources, put together by Global MarketsDirect’s team.Note*: Certain sections in the report may be removed or altered based onthe availability and relevance of data for the indicated disease.
Scope - A snapshot of the global therapeutic scenario for Metastatic HormoneRefractory Prostate Cancer.- A review of the Metastatic Hormone Refractory Prostate Cancer productsunder development by companies and universities/research institutes based oninformation derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Metastatic Hormone Refractory Prostate Cancer.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the mostpromising pipeline.
Table of Contents : List of Tables 6List of Figures 7Introduction 8Global Markets Direct Report Coverage 8Metastatic Hormone Refractory Prostate Cancer Overview 9Therapeutics Development 10An Overview of Pipeline Products for Metastatic Hormone RefractoryProstate Cancer 10Metastatic Hormone Refractory Prostate Cancer Therapeutics underDevelopment by Companies 12Metastatic Hormone Refractory Prostate Cancer Therapeutics underInvestigation by Universities/Institutes 14Late Stage Products 16Comparative Analysis 16Mid Clinical Stage Products 17Comparative Analysis 17Early Clinical Stage Products 18Comparative Analysis 18……………………..
Please follow link if you want More RelatedReports :Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=PipelineReview, H2 2012&PubId=&pagenum=1
For More details about above & otherReports plz contact :LavanyaAarkstore.comContact: Marketing team Mob.No.918149852585Email: firstname.lastname@example.org ,email@example.comURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore